Danaher Raises 2025 Earnings Outlook
Danaher (NYSE:DHR) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free cash flow hit $1.1 billion, and management raised full-year adjusted diluted net EPS guidance to $7.70–$7.80. The call addressed the company's CFO succession plan, sector-specific momentum, and notable tariff and China headwinds, and reaffirmed a high single-digit percentage long-term core growth outlook for bioprocessing.
Danaher’s biotechnology segment, anchored by its $6 billion bioprocessing business, reported 6% core revenue growth, led by low double-digit percentage consumables growth and robust order trends, particularly from large pharma contract manufacturers. Although equipment sales declined and global trade volatility suppressed larger-scale capital decisions, bioprocessing’s profitability in the first half of 2025 was strong.
Sustained high growth in consumables, despite capital spending pauses, significantly enhances Danaher’s recurring revenue visibility. This secures the bioprocessing franchise’s role as the company’s primary long-term growth driver.
Source Fool.com
Danaher Corp. Aktie
Die Danaher Corp. Aktie in der Gunst der Community: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Kursziel von 226 € für Danaher Corp. weist auf eine Steigerung von über 20% gegenüber dem aktuellen Kurs von 164.52 € hin.
